Literature DB >> 18180387

Xenotransplantation in orthopaedic surgery.

Cato T Laurencin1, Saadiq F El-Amin.   

Abstract

We define xenotransplantation as including any procedure that involves the transplantation, implantation, or infusion into a human recipient of cells, tissues, or organs from a nonhuman animal source or of human body fluids, cells, tissues, or organs that have had ex vivo contact with nonhuman animal cells, tissues, or organs. The current FDA definition of xenotransplantation relates to procedures involving live, nonhuman materials. The proposed use of xenotransplanted tissues for treatment of a wide variety of human diseases is increasing. In orthopaedic surgery, a number of xeno-based products for treatment of musculoskeletal conditions have been cleared by the FDA. Commercially available products include those used as alternatives for bone, cartilage, and soft-tissue repair. Most xenografts are from bovine- or porcine-derived sources. Studies internationally have demonstrated a low relative risk of disease transmission, although there is concern regarding the potential for transmission into humans of agents not considered pathogenic or not detected in animals.

Entities:  

Mesh:

Year:  2008        PMID: 18180387     DOI: 10.5435/00124635-200801000-00002

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  18 in total

1.  Bone grafts in craniofacial surgery.

Authors:  Mohammed E Elsalanty; David G Genecov
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2009-10

Review 2.  [Bone substitute. Transplants and replacement materials--an update].

Authors:  C Rentsch; B Rentsch; D Scharnweber; H Zwipp; S Rammelt
Journal:  Unfallchirurg       Date:  2012-10       Impact factor: 1.000

3.  Xenotransplantation of human mesenchymal stem cells for repair of osteochondral defects in rabbits using osteochondral biphasic composite constructs.

Authors:  Ki-Mo Jang; Ju-Han Lee; Chan Mi Park; Hae-Ryong Song; Joon Ho Wang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-01-31       Impact factor: 4.342

4.  Injectable biomaterials for regenerating complex craniofacial tissues.

Authors:  James D Kretlow; Simon Young; Leda Klouda; Mark Wong; Antonios G Mikos
Journal:  Adv Mater       Date:  2009-09-04       Impact factor: 30.849

5.  Combined use of RGD-peptide modified PLGA and TGF-beta1 gene transfected MSCs to improve cell biobehaviors in vitro.

Authors:  Changwen Li; Qixin Zheng; Xiaodong Guo; Daping Quan; Jie Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

6.  Comparison of Phenotypic Characterization between Differentiated Osteoblasts from Stem Cells and Calvaria Osteoblasts In vitro.

Authors:  Batool Hashemibeni; Farzaneh Jafary; Nafiseh Esmaeil; Vahid Goharian; Ghader Feizi; Fariba Heidari; Sayyedeh Zahra Moosavi-Nejad; Sayyed Hamid Zarkesh
Journal:  Int J Prev Med       Date:  2013-02

7.  Comparative study of subtalar arthrodesis after calcaneal frature malunion with autologous bone graft or freeze-dried xenograft.

Authors:  Carlo Henning; Gabriel Poglia; Murilo Anderson Leie; Carlos Roberto Galia
Journal:  J Exp Orthop       Date:  2015-05-07

8.  Osteoinduction and proliferation of bone-marrow stromal cells in three-dimensional poly (ε-caprolactone)/ hydroxyapatite/collagen scaffolds.

Authors:  Ting Wang; Xiaoyan Yang; Xin Qi; Chaoyin Jiang
Journal:  J Transl Med       Date:  2015-05-08       Impact factor: 5.531

9.  Various Dosages of BMP-2 for Management of Massive Bone Defect in Sprague Dawley Rat.

Authors:  Achmad Fauzi Kamal; Othdeh Samuel Halomoan Siahaan; Jessica Fiolin
Journal:  Arch Bone Jt Surg       Date:  2019-11

Review 10.  The deep-sea natural products, biogenic polyphosphate (Bio-PolyP) and biogenic silica (Bio-Silica), as biomimetic scaffolds for bone tissue engineering: fabrication of a morphogenetically-active polymer.

Authors:  Xiaohong Wang; Heinz C Schröder; Qingling Feng; Florian Draenert; Werner E G Müller
Journal:  Mar Drugs       Date:  2013-03-08       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.